vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v13i2.975vsp-209Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEКОКЛЮШ — НЕДОУПРАВЛЯЕМАЯ ИНФЕКЦИЯPERTUSSIS — INFECTION NOT UNDER COMPLETE CONTROLТаточенкоВ. К.TatochenkoV. K.

Vladimir Tatochenko, Doctor of Medical Science, professor, chief research scientist

tatovk@yandex.ruНаучный центр здоровья детей, МоскваРоссияScientific Centre of Children Health, MoscowRussian Federation201401042014132Вопросы современной педиатрии7882Copyright © Таточенко В.К., 20142014Таточенко В.К.Tatochenko V.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/209

Статья посвящена актуальности проблемы коклюша у детей различного возраста и причинам высокой заболеваемости этой инфекцией в Российской Федерации. Основными факторами неблагополучия по коклюшу автор считает недостаточный учет случаев инфекции, увеличение числа отказов родителей от АКДС-вакцинации, постепенное угасание напряженности постпрививочного иммунитета и низкий уровень защиты у детей перед поступлением в школу, а также сложности диагностики инфекции и атипичное течение заболевания у подростков и взрослых. Особое внимание уделено обзору современных дискуссий по вопросам изменчивости возбудителя, сравнительной эффективности и иммуногенности цельноклеточных и ацеллюлярных вакцин и международному опыту перехода использование бесклеточных АКДС-вакцин. Возможными путями улучшения эпидемиологической ситуации и улучшения контроля коклюшной инфекцией могут стать повышение уровня охвата прививками (за счет перехода на менее реактогенные АаКДС), введение бустерных доз в младшем школьном и подростковом возрасте, вакцинация беременных и стратегия «кокона» для защиты новорожденных и детей до 6 мес жизни.

 

коклюшвакцинацияцельноклеточные и бесклеточные вакцинывторая бустерная дозакоконpertussisvaccinationwhole cell and acellular vaccinessecond booster dosagecocooningReferencesO sanitarno-epidemiologicheskoy obstanovke v Rossiyskoy Federatsii v 2009 g.: Gosudarstvennyy doklad [On Sanitary and Epidemiologic Situation in the Russian Federation in 2009: State Report]. М.: 2010. 456 p.O sanitarno-epidemiologicheskoy obstanovke v Rossiyskoy Federatsii v 2009 g.: Gosudarstvennyy doklad [On Sanitary and Epidemiologic Situation in the Russian Federation in 2009: State Report]. М.: 2010. 456 p.Hawken S., Manuel D. G., Deeks S. L., Kwong J. C., Crowcroft N. S., Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am. J. Epidemiol. 2012; 176 (11): 1035–1042.Hawken S., Manuel D. G., Deeks S. L., Kwong J. C., Crowcroft N. S., Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am. J. Epidemiol. 2012; 176 (11): 1035–1042.Zaytsev Ye. M., Mazurova I. K., Krasnoproshina L. I., Astakhova T. I., Zakharova N. S. Zhurnal mikrobiologii, epidemiologii i immunologii — Journal of Epidemiology, Microbiology and Immunology. 2009; 1: 56–58.Zaytsev Ye. M., Mazurova I. K., Krasnoproshina L. I., Astakhova T. I., Zakharova N. S. Zhurnal mikrobiologii, epidemiologii i immunologii — Journal of Epidemiology, Microbiology and Immunology. 2009; 1: 56–58.Epidemiologicheskiye aspekty koklyusha v RF. Osobennosti vakt sinoprofilaktiki v sovremennykh usloviyakh [Epidemiological Aspects of Whooping Cough in the Russian Federation. Features of Vaccinal Prevention in Modern Conditions]. М.: MZ RF. 2005. 38 p.Epidemiologicheskiye aspekty koklyusha v RF. Osobennosti vakt sinoprofilaktiki v sovremennykh usloviyakh [Epidemiological Aspects of Whooping Cough in the Russian Federation. Features of Vaccinal Prevention in Modern Conditions]. М.: MZ RF. 2005. 38 p.Zaytsev Ye. M., Mazurova I. K., Petrova M. S. Zhurnal mikrobiologii, epidemiologii i immunologii — Journal of Epidemiology, Microbiology and Immunology. 2009; 2: 70–75.Zaytsev Ye. M., Mazurova I. K., Petrova M. S. Zhurnal mikrobiologii, epidemiologii i immunologii — Journal of Epidemiology, Microbiology and Immunology. 2009; 2: 70–75.Narkeviciute I., Kavaliunaite E., Bernatoniene G., Eidukevicius R. Clinical presentation of pertussis in fully immunized children in Lithuania. BMC Infect. Dis. 2005; 5: 40. Doi: 10.1186/ 1471-2334-5-40.Narkeviciute I., Kavaliunaite E., Bernatoniene G., Eidukevicius R. Clinical presentation of pertussis in fully immunized children in Lithuania. BMC Infect. Dis. 2005; 5: 40. Doi: 10.1186/ 1471-2334-5-40.Celentano L. P., Massari M., Paramatti D., Salmaso S., Tozzi A. E. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 2005: 24: 761–765.Celentano L. P., Massari M., Paramatti D., Salmaso S., Tozzi A. E. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 2005: 24: 761–765.Halperin S. A. The Control of Pertussis — 2007 and Beyond. N. Engl. J. Med. 2007; 356 (2): 6110–6112.Halperin S. A. The Control of Pertussis — 2007 and Beyond. N. Engl. J. Med. 2007; 356 (2): 6110–6112.Iozefovich O. V., Kharit S. M., Kaplina S. P., Gostev V. V., Sidorenko S. V., Kalinogorskaya O. S., Kvetnaya A. S., Timofeyeva Ye. V., Okuneva M. A. Epidemiologiya i vaktsinoprofilaktika — Epidemiology and Vaccinal Prevention. 2012; 56–59.Iozefovich O. V., Kharit S. M., Kaplina S. P., Gostev V. V., Sidorenko S. V., Kalinogorskaya O. S., Kvetnaya A. S., Timofeyeva Ye. V., Okuneva M. A. Epidemiologiya i vaktsinoprofilaktika — Epidemiology and Vaccinal Prevention. 2012; 56–59.Schmidtke A. J., Boney K. O., Martin S. W. Population Diversity among Bordetella pertussis isolates, United States, 1935–2009. Emerging Infect. Dis. 2012; 18 (8): 1248–1255.Schmidtke A. J., Boney K. O., Martin S. W. Population Diversity among Bordetella pertussis isolates, United States, 1935–2009. Emerging Infect. Dis. 2012; 18 (8): 1248–1255.Queenan А. M., Cassiday P. K., Evangelista A. Pertactin-Negative variants of Bordetella pertussis in the United States. N. Engl. J. Med. 2013; 368: 583–584.Queenan А. M., Cassiday P. K., Evangelista A. Pertactin-Negative variants of Bordetella pertussis in the United States. N. Engl. J. Med. 2013; 368: 583–584.Rodgers L., Martin S. W., Cohn A., Budd J., Marcon M., Terranella A., Mandal S., Salamon D., Leber A., Tondella M. L., Tatti K., Spicer K., Emanuel A., Koch E., McGlone L., Pawloski L., LemaileWilliams M., Tucker N., Iyer R., Clark T. A., Diorio M. Epidemiologic and laboratory features of a large outbreak of pertussislike illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010–2011. Clin. Infect. Dis. 2013; 56: 322–331.Rodgers L., Martin S. W., Cohn A., Budd J., Marcon M., Terranella A., Mandal S., Salamon D., Leber A., Tondella M. L., Tatti K., Spicer K., Emanuel A., Koch E., McGlone L., Pawloski L., LemaileWilliams M., Tucker N., Iyer R., Clark T. A., Diorio M. Epidemiologic and laboratory features of a large outbreak of pertussislike illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010–2011. Clin. Infect. Dis. 2013; 56: 322–331.Atwell J. E., Van Otterloo J., Zipprich J., Winter K., Harriman K., Salmon D. A., Halsey N. A., Omer S. B. Nonmedical Vaccine Exemptions and Pertussis in California, 2010. Pediatrics. 2013; doi: 10.1542/peds.2013-0878.Atwell J. E., Van Otterloo J., Zipprich J., Winter K., Harriman K., Salmon D. A., Halsey N. A., Omer S. B. Nonmedical Vaccine Exemptions and Pertussis in California, 2010. Pediatrics. 2013; doi: 10.1542/peds.2013-0878.Auger К. A., Patrick S. W., Davis M. M. Infant hospitalizations for pertussis before and after Tdap recommendations for adolescents. Pediatrics. 2013; 132: 1149–1155.Auger К. A., Patrick S. W., Davis M. M. Infant hospitalizations for pertussis before and after Tdap recommendations for adolescents. Pediatrics. 2013; 132: 1149–1155.Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., Tozzi A. E., Van Damme P. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 2011; 11 (7): 557–570. Doi: 10.1016/S1473-3099 (11)70007-X.Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., Tozzi A. E., Van Damme P. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 2011; 11 (7): 557–570. Doi: 10.1016/S1473-3099 (11)70007-X.Tartof S. Y., Lewis M., Kenyon C., White K., Osborn A., Liko J., Zell E., Martin S., Messonnier N. E., Clark T. A., Skoff T. H. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013; 131 (4): 1047–1052. Doi: 10.1542/peds.2012-1928.Tartof S. Y., Lewis M., Kenyon C., White K., Osborn A., Liko J., Zell E., Martin S., Messonnier N. E., Clark T. A., Skoff T. H. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013; 131 (4): 1047–1052. Doi: 10.1542/peds.2012-1928.Klein N. P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. PLoS One. 2012; 7 (7): 41928. Doi: 10.1371/journal. pone.0041928.Klein N. P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. PLoS One. 2012; 7 (7): 41928. Doi: 10.1371/journal. pone.0041928.Liko J., Robison S. G., Cieslak P. R. Priming with whole-cell versus acellular pertussis vaccine. N. Engl. J. Med. 2013; 368: 581–582.Liko J., Robison S. G., Cieslak P. R. Priming with whole-cell versus acellular pertussis vaccine. N. Engl. J. Med. 2013; 368: 581–582.Witt M. A., Arias L., Katz P. H., Truong E. T., Witt D. J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine ompared to recipients of acellular pertussis vaccines in a large US cohort. CID. 2013; 56: 1248–1255.Witt M. A., Arias L., Katz P. H., Truong E. T., Witt D. J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine ompared to recipients of acellular pertussis vaccines in a large US cohort. CID. 2013; 56: 1248–1255.Schure R. M., de Rond L., Ozturk K., Hendrikx L., Sanders E., Berbers G., Buisman A. M. Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One. 2012; 7 (7): 41928. Doi: 10.1371/journal.pone.0041928.Schure R. M., de Rond L., Ozturk K., Hendrikx L., Sanders E., Berbers G., Buisman A. M. Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One. 2012; 7 (7): 41928. Doi: 10.1371/journal.pone.0041928.Thierry-Carstensen B. et al. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults — A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013; http://dx.doi.org/10.1016/j. vaccine.2013.08.034Thierry-Carstensen B. et al. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults — A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013; http://dx.doi.org/10.1016/j. vaccine.2013.08.034Dias W. O., van der Ark A. A., Sakauchi M. A., Kubrusly F. S., Prestes A. F., Borges M. M., Furuyama N., Horton D. S., Quintilio W., Antoniazi M., Kuipers B., van der Zeijst B. A., Raw I. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother. 2013; 9 (2): Epub ahead of print.Dias W. O., van der Ark A. A., Sakauchi M. A., Kubrusly F. S., Prestes A. F., Borges M. M., Furuyama N., Horton D. S., Quintilio W., Antoniazi M., Kuipers B., van der Zeijst B. A., Raw I. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother. 2013; 9 (2): Epub ahead of print.Committee opinion no. 566: update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet. Gynecol. 2013; 121 (6): 1411–1414.Committee opinion no. 566: update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet. Gynecol. 2013; 121 (6): 1411–1414.Hardy-Fairbanks A. J., Pan S. J., Decker M. D., Johnson D. R., Greenberg D. P., Kirkland K. B., Talbot E. A., Bernstein H. H. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr. Infect. Dis. J. 2013; 32 (11): 1257–1260. Doi: 10.1097/INF.0b013e3182a09b6a.Hardy-Fairbanks A. J., Pan S. J., Decker M. D., Johnson D. R., Greenberg D. P., Kirkland K. B., Talbot E. A., Bernstein H. H. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr. Infect. Dis. J. 2013; 32 (11): 1257–1260. Doi: 10.1097/INF.0b013e3182a09b6a.

The authors declare that there are no conflicts of interest present.